10X Genomics Inc
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and … Read more
10X Genomics Inc (TXG) - Total Assets
Latest total assets as of September 2025: $1.03 Billion USD
Based on the latest financial reports, 10X Genomics Inc (TXG) holds total assets worth $1.03 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
10X Genomics Inc - Total Assets Trend (2017–2024)
This chart illustrates how 10X Genomics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
10X Genomics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
10X Genomics Inc's total assets of $1.03 Billion consist of 63.6% current assets and 36.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 37.5% |
| Accounts Receivable | $87.86 Million | 9.6% |
| Inventory | $83.11 Million | 9.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $15.67 Million | 1.7% |
| Goodwill | $4.51 Million | 0.5% |
Asset Composition Trend (2017–2024)
This chart illustrates how 10X Genomics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 10X Genomics Inc's current assets represent 63.6% of total assets in 2024, a decrease from 90.1% in 2017.
- Cash Position: Cash and equivalents constituted 37.5% of total assets in 2024, down from 63.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 9.6% of total assets.
10X Genomics Inc Competitors by Total Assets
Key competitors of 10X Genomics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
UCrest Bhd
KLSE:0005
|
Malaysia | RM48.46 Million |
|
Vanfund Urban Investment & Development Co Ltd
SHE:000638
|
China | CN¥265.74 Million |
|
BIT Computer Co. Ltd
KQ:032850
|
Korea | ₩82.38 Billion |
|
ezCaretech Co. LTD
KQ:099750
|
Korea | ₩56.71 Billion |
|
SyntekaBio Inc
KQ:226330
|
Korea | ₩33.49 Billion |
|
Carelabs Co.Ltd
KQ:263700
|
Korea | ₩105.15 Billion |
|
Shanghai Kingstar Winning Software
SHE:300253
|
China | CN¥8.35 Billion |
|
Longmaster Information Tech
SHE:300288
|
China | CN¥1.33 Billion |
10X Genomics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - 10X Genomics Inc generates 0.66x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - 10X Genomics Inc is currently not profitable relative to its asset base.
10X Genomics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.48 | 4.90 | 6.56 |
| Quick Ratio | 4.06 | 4.12 | 6.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $512.50 Million | $ 472.66 Million | $ 656.24 Million |
10X Genomics Inc - Advanced Valuation Insights
This section examines the relationship between 10X Genomics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.00 |
| Latest Market Cap to Assets Ratio | 2.16 |
| Asset Growth Rate (YoY) | -4.8% |
| Total Assets | $918.64 Million |
| Market Capitalization | $1.98 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values 10X Genomics Inc's assets at a significant premium ( 2.16x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: 10X Genomics Inc's assets decreased by 4.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for 10X Genomics Inc (2017–2024)
The table below shows the annual total assets of 10X Genomics Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $918.64 Million | -4.82% |
| 2023-12-31 | $965.14 Million | -6.20% |
| 2022-12-31 | $1.03 Billion | +1.00% |
| 2021-12-31 | $1.02 Billion | +9.63% |
| 2020-12-31 | $929.34 Million | +53.38% |
| 2019-12-31 | $605.92 Million | +387.43% |
| 2018-12-31 | $124.31 Million | +64.41% |
| 2017-12-31 | $75.61 Million | -- |